12/1
09:22 am
mxct
Cellares Appoints Former MaxCyte Commercial Chief Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion, Catalyze Next Wave of Partnerships, Prepare for IPO [Yahoo! Finance]
Medium
Report
Cellares Appoints Former MaxCyte Commercial Chief Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion, Catalyze Next Wave of Partnerships, Prepare for IPO [Yahoo! Finance]
12/1
09:00 am
mxct
Cellares Appoints Former MaxCyte Commercial Chief Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion, Catalyze Next Wave of Partnerships, Prepare for IPO
Medium
Report
Cellares Appoints Former MaxCyte Commercial Chief Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion, Catalyze Next Wave of Partnerships, Prepare for IPO
11/25
01:54 pm
mxct
MaxCyte (NASDAQ:MXCT) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
MaxCyte (NASDAQ:MXCT) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/22
02:11 am
mxct
Neutral
Report
11/22
02:11 am
mxct
Neutral
Report
11/18
01:18 pm
mxct
MaxCyte (NASDAQ:MXCT) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
MaxCyte (NASDAQ:MXCT) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/13
06:16 am
mxct
MaxCyte reports Q3 results [Seeking Alpha]
Low
Report
MaxCyte reports Q3 results [Seeking Alpha]
11/13
12:12 am
mxct
MaxCyte Inc (MXCT) Q3 2025 Earnings Call Highlights: Strategic Moves Amidst Market Challenges [Yahoo! Finance]
Low
Report
MaxCyte Inc (MXCT) Q3 2025 Earnings Call Highlights: Strategic Moves Amidst Market Challenges [Yahoo! Finance]
11/12
07:14 pm
mxct
MaxCyte, Inc. (MXCT) Q3 2025 Earnings Call Transcript [Seeking Alpha]
Low
Report
MaxCyte, Inc. (MXCT) Q3 2025 Earnings Call Transcript [Seeking Alpha]
11/12
07:14 pm
mxct
MaxCyte outlines $17M–$19M annualized savings through restructuring while reiterating SPL revenue guidance [Seeking Alpha]
Low
Report
MaxCyte outlines $17M–$19M annualized savings through restructuring while reiterating SPL revenue guidance [Seeking Alpha]
11/12
04:53 pm
mxct
MaxCyte Announces Planned CFO Transition in 2026 [Yahoo! Finance]
Low
Report
MaxCyte Announces Planned CFO Transition in 2026 [Yahoo! Finance]
11/12
04:36 pm
mxct
MaxCyte CFO to step down in first half of 2026 [Seeking Alpha]
Low
Report
MaxCyte CFO to step down in first half of 2026 [Seeking Alpha]
11/12
04:08 pm
mxct
MaxCyte Announces Planned CFO Transition in 2026
Low
Report
MaxCyte Announces Planned CFO Transition in 2026
11/12
04:05 pm
mxct
MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance
Low
Report
MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance
11/12
01:27 pm
mxct
MaxCyte (NASDAQ:MXCT) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
MaxCyte (NASDAQ:MXCT) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/5
08:05 am
mxct
MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance
Medium
Report
MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance
10/8
08:05 am
mxct
MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025
Medium
Report
MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025
10/6
08:49 am
mxct
MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors [Yahoo! Finance]
Medium
Report
MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors [Yahoo! Finance]
10/6
08:05 am
mxct
MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors
Medium
Report
MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors
9/22
04:56 pm
mxct
MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability [Yahoo! Finance]
Medium
Report
MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability [Yahoo! Finance]
9/22
04:30 pm
mxct
MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability
High
Report
MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability